Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $46.80 million. The enterprise value is $92.50 million.
Important Dates
The next estimated earnings date is Wednesday, August 6, 2025, after market close.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 146.56 million shares outstanding. The number of shares has increased by 63.31% in one year.
| Current Share Class | 146.56M |
| Shares Outstanding | 146.56M |
| Shares Change (YoY) | +63.31% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 50.77% |
| Owned by Institutions (%) | 30.98% |
| Float | 61.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.59 |
| Forward PS | 0.52 |
| PB Ratio | 4.11 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.22, with a Debt / Equity ratio of 5.77.
| Current Ratio | 2.22 |
| Quick Ratio | 1.90 |
| Debt / Equity | 5.77 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.37 |
Financial Efficiency
Return on equity (ROE) is -1,454.41% and return on invested capital (ROIC) is -30.82%.
| Return on Equity (ROE) | -1,454.41% |
| Return on Assets (ROA) | -23.33% |
| Return on Invested Capital (ROIC) | -30.82% |
| Return on Capital Employed (ROCE) | -44.39% |
| Revenue Per Employee | $272,758 |
| Profits Per Employee | -$148,051 |
| Employee Count | 273 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 12.88 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.89% in the last 52 weeks. The beta is 0.96, so Biodesix's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | -82.89% |
| 50-Day Moving Average | 0.30 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 50.89 |
| Average Volume (20 Days) | 846,186 |
Short Selling Information
The latest short interest is 4.91 million, so 3.35% of the outstanding shares have been sold short.
| Short Interest | 4.91M |
| Short Previous Month | 5.26M |
| Short % of Shares Out | 3.35% |
| Short % of Float | 7.92% |
| Short Ratio (days to cover) | 0.23 |
Income Statement
In the last 12 months, Biodesix had revenue of $74.46 million and -$40.42 million in losses. Loss per share was -$0.28.
| Revenue | 74.46M |
| Gross Profit | 58.36M |
| Operating Income | -32.37M |
| Pretax Income | n/a |
| Net Income | -40.42M |
| EBITDA | -26.58M |
| EBIT | -32.37M |
| Loss Per Share | -$0.28 |
Full Income StatementBalance Sheet
The company has $17.60 million in cash and $63.87 million in debt, giving a net cash position of -$46.26 million or -$0.32 per share.
| Cash & Cash Equivalents | 17.60M |
| Total Debt | 63.87M |
| Net Cash | -46.26M |
| Net Cash Per Share | -$0.32 |
| Equity (Book Value) | 11.06M |
| Book Value Per Share | 0.08 |
| Working Capital | 16.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$41.94 million and capital expenditures -$3.07 million, giving a free cash flow of -$45.01 million.
| Operating Cash Flow | -41.94M |
| Capital Expenditures | -3.07M |
| Free Cash Flow | -45.01M |
| FCF Per Share | -$0.31 |
Full Cash Flow StatementMargins
Gross margin is 78.38%, with operating and profit margins of -43.47% and -54.28%.
| Gross Margin | 78.38% |
| Operating Margin | -43.47% |
| Pretax Margin | -54.28% |
| Profit Margin | -54.28% |
| EBITDA Margin | -35.69% |
| EBIT Margin | -43.47% |
| FCF Margin | n/a |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -63.31% |
| Shareholder Yield | -63.31% |
| Earnings Yield | -87.41% |
| FCF Yield | -97.34% |
Analyst Forecast
The average price target for Biodesix is $1.75, which is 448.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $1.75 |
| Price Target Difference | 448.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biodesix has an Altman Z-Score of -6.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.27 |
| Piotroski F-Score | 3 |
